• Molecular NameMexiletine
  • SynonymMexiletina [INN-Spanish]; Mexiletine HCL; Mexiletinum [INN-Latin]; Mexilitine
  • Weight179.263
  • Drugbank_IDDB00379
  • ACS_NO31828-71-4
  • Show 3D model
  • LogP (experiment)2.039
  • LogP (predicted, AB/LogP v2.0)2.32
  • pka9.2
  • LogD (pH=7, predicted)0.26
  • Solubility (experiment)8.25 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-0.28
  • LogSw (predicted, AB/LogsW2.0)0.36
  • Sw (mg/ml) (predicted, ACD/Labs)2.54
  • No.of HBond Donors2
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds3
  • TPSA35.25
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyIt is used to treat arrhythmias within the heart - or seriously irregular heartbeats. It slows nerve impulses in the heart and makes the heart tissue less sensitive. Dizziness, heartburn, nausea, nervousness, trembling, unsteadiness are common side effects. It is available in injection and capsule form.
  • Absorption_value98.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability87.0
  • Protein binding55.0
  • Volume of distribution (VD)8 L/kg but there is considerable intersubject variation.
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (CYP2D6 and 1A2- mediated)
  • Half life7 to 25 h (mean 11 h in normal subjects, increased in subjects with arrhythmias).
  • ExcretionRenal (10%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include nausea, hypotension, sinus bradycardia, paresthesia, seizures, bundle branch block, AV heart block, asystole, ventricular tachyarrythmia, including ventricular fibrillation, cardiovascular collapse, and coma.
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=114 (ip)